Litcius/Paper detail

Docking and mutagenesis studies lead to improved inhibitor development of ML355 for human platelet 12-lipoxygenase

Wan‐Chen Tsai, Ansari M. Aleem, Jennyfer Tena, Mirella Rivera-Velazquez, Harman Brah, Sarvind Tripathi, Melinee D’silva, Jerry L. Nadler, Chakrapani Kalyanaraman, Matthew P. Jacobson, Theodore R. Holman

2021Bioorganic & Medicinal Chemistry14 citationsDOIOpen Access PDF

Topics & Concepts

ChemistryBenzothiazoleADMEPotencyDocking (animal)Active siteStereochemistryBinding siteLinkerBiochemistryLipoxygenasePharmacologyEnzymeIn vitroNursingOperating systemComputer scienceMedicineAdenosine and Purinergic SignalingReceptor Mechanisms and SignalingSphingolipid Metabolism and Signaling
Docking and mutagenesis studies lead to improved inhibitor development of ML355 for human platelet 12-lipoxygenase | Litcius